Skip to main content
Erschienen in: Skeletal Radiology 7/2005

01.07.2005 | Scientific Article

18FDG-PET applications for cartilage neoplasms

verfasst von: Frieda Feldman, Ronald Van Heertum, Chitra Saxena, May Parisien

Erschienen in: Skeletal Radiology | Ausgabe 7/2005

Einloggen, um Zugang zu erhalten

Abstract

Objective

To assess the value of [18F]fluoro-2-deoxy-d-glucose positron emission tomography (18FDG-PET) in defining aggressive cartilage neoplasms, particularly those with problematic or borderline histologic, imaging and clinical characteristics.

Design and patients

From 2000 to 2003, 29 cartilage lesions were studied with whole-body 18FDG-PET scans (Siemens Ecat Exact, Knoxville, Tenn.). Analyses of data in 20 females and nine males, 11–85 years old, were based on maximum standard uptake values (SUVs) in regions of interest (ROIs) on axial 3.37 mm thick, 3×3 pixel images. A statistically significant maximum SUV cutoff of 2.0 was used to distinguish benign from malignant cartilage neoplasms and correlated with the postoperative histopathologic findings.

Results

In 26 operated cases the overall sensitivity of whole-body 18FDG-PET in separating benign and malignant lesions was 90.9% (10/11), specificity 100% (18/18) and accuracy 96.6%.

Conclusions

Whole-body 18FDG-PET is a valuable adjunct in identifying primary, recurrent and metastatic cartilage malignancies. It supplements classic histology and morphologic imaging with functional data which may facilitate management in individual cases.
Literatur
1.
Zurück zum Zitat Evans HL, Ayala AG, Romsdah MM. Prognostic factors in chondrosarcoma of bone. Cancer 1977; 40:818–831. Evans HL, Ayala AG, Romsdah MM. Prognostic factors in chondrosarcoma of bone. Cancer 1977; 40:818–831.
2.
Zurück zum Zitat Mankin HJ, Lange TA, Spanier SS. The hazards of biopsy in patients with malignant primary bone and soft tissue tumors J Bone Joint Surg Am 1982; 64:1121–1127. Mankin HJ, Lange TA, Spanier SS. The hazards of biopsy in patients with malignant primary bone and soft tissue tumors J Bone Joint Surg Am 1982; 64:1121–1127.
3.
Zurück zum Zitat Rosenthal DJ, Schiller AL, Mankin HJ. Chondrosarcoma: correlation of radiological and histological grade. Radiology 1984; 150:21–26.PubMed Rosenthal DJ, Schiller AL, Mankin HJ. Chondrosarcoma: correlation of radiological and histological grade. Radiology 1984; 150:21–26.PubMed
4.
Zurück zum Zitat Unni K. Dahlin’s bone tumors: general aspects and data on 11,087 cases, 5th edn. Philadelphia: Lippincott-Raven, 1996:143–183. Unni K. Dahlin’s bone tumors: general aspects and data on 11,087 cases, 5th edn. Philadelphia: Lippincott-Raven, 1996:143–183.
5.
Zurück zum Zitat Som P, Atkins HL, Bandaypadhyay D, et al. A fluorinated glucose analog, 2-fluoro-2-glucose (F18): nontoxic tracer for rapid tumor detection. J Nucl Med 1980; 21:670–675.PubMed Som P, Atkins HL, Bandaypadhyay D, et al. A fluorinated glucose analog, 2-fluoro-2-glucose (F18): nontoxic tracer for rapid tumor detection. J Nucl Med 1980; 21:670–675.PubMed
6.
Zurück zum Zitat Messa C, Landoni C, Pozzaato C, et al. Is there a role for FDG-PET in the diagnosis of musculoskeletal neoplasms? J Nucl Med 2000; 41:170–317[AU: PLEASE CHECK PAGE NOS.]. Messa C, Landoni C, Pozzaato C, et al. Is there a role for FDG-PET in the diagnosis of musculoskeletal neoplasms? J Nucl Med 2000; 41:170–317[AU: PLEASE CHECK PAGE NOS.].
7.
Zurück zum Zitat Cook G, Fogelman I. The role of positron emission tomography in skeletal disease. Semin Nucl Med 2001; 31:50–61.PubMed Cook G, Fogelman I. The role of positron emission tomography in skeletal disease. Semin Nucl Med 2001; 31:50–61.PubMed
8.
Zurück zum Zitat Kole AC, Nieweg OE, Hoekstra HJ, et al. F18 assessment of glucose metabolism in bone tumors. J Nucl Med 1998; 39:810–815.PubMed Kole AC, Nieweg OE, Hoekstra HJ, et al. F18 assessment of glucose metabolism in bone tumors. J Nucl Med 1998; 39:810–815.PubMed
9.
Zurück zum Zitat Kern KA, Brunetti A, Norton JA, et al. Metabolic imaging of human extremity musculoskeletal tumors by PET. J Nucl Med 1998; 29:181–186. Kern KA, Brunetti A, Norton JA, et al. Metabolic imaging of human extremity musculoskeletal tumors by PET. J Nucl Med 1998; 29:181–186.
10.
Zurück zum Zitat Dehdashti FD, Siegel GA, Griffeth LK, et al. Benign vs malignant intraosseous lesions: discrimination by means of PET with 2-(F18)-fluoro-2-deoxy-d-glucose. Radiology 1996; 200:243–247.PubMed Dehdashti FD, Siegel GA, Griffeth LK, et al. Benign vs malignant intraosseous lesions: discrimination by means of PET with 2-(F18)-fluoro-2-deoxy-d-glucose. Radiology 1996; 200:243–247.PubMed
11.
Zurück zum Zitat Eary JF, Conrad E, Bruckner JD, et al Quantitative (F18) fluorodeoxyglucose positron emission tomography in pretreatment and grading of sarcoma. Clin Cancer Res 1998; 4:1215–1220. Eary JF, Conrad E, Bruckner JD, et al Quantitative (F18) fluorodeoxyglucose positron emission tomography in pretreatment and grading of sarcoma. Clin Cancer Res 1998; 4:1215–1220.
12.
Zurück zum Zitat Brenner W, Conrad EU, Eary JF. FDG PET imaging for grading and prediction of outcome in chondrosarcoma patients. Eur J Nucl Med Mol Imaging 2004; 31:189–195.CrossRefPubMed Brenner W, Conrad EU, Eary JF. FDG PET imaging for grading and prediction of outcome in chondrosarcoma patients. Eur J Nucl Med Mol Imaging 2004; 31:189–195.CrossRefPubMed
13.
Zurück zum Zitat Schulte M, Brecht-Krauss D, Heymer B, et al. Grading of tumors and tumorlike lesions of bone: evaluation by FDG PET. J Nucl Med 2000; 41:1695–1701.PubMed Schulte M, Brecht-Krauss D, Heymer B, et al. Grading of tumors and tumorlike lesions of bone: evaluation by FDG PET. J Nucl Med 2000; 41:1695–1701.PubMed
14.
Zurück zum Zitat Gilkey FW, Moser RP. The biology of cartilage. In: Moser RP, ed. Cartilaginous tumors of the skeleton. Philadelphia: Hanley and Belfus, 1990:1–7. Gilkey FW, Moser RP. The biology of cartilage. In: Moser RP, ed. Cartilaginous tumors of the skeleton. Philadelphia: Hanley and Belfus, 1990:1–7.
15.
Zurück zum Zitat Feldman F, VanHeertum R, Manoj C.18FDG PET scanning of benign and malignant musculoskeletal lesions. Skeletal Radiol 2003; 32:201–208.PubMed Feldman F, VanHeertum R, Manoj C.18FDG PET scanning of benign and malignant musculoskeletal lesions. Skeletal Radiol 2003; 32:201–208.PubMed
16.
Zurück zum Zitat Aoki J, Watanabe H, Shinozaki T, et al. FDG PET in differential diagnosis and grading of chondrosarcomas. J Comput Assist Tomogr 1999; 23:603–608.CrossRefPubMed Aoki J, Watanabe H, Shinozaki T, et al. FDG PET in differential diagnosis and grading of chondrosarcomas. J Comput Assist Tomogr 1999; 23:603–608.CrossRefPubMed
17.
Zurück zum Zitat Aoki J, Watanabe H, Shinozaki T, et al. FDG PET of primary benign and malignant bone tumors: standardized uptake value in 52 lesions. Radiology 2001; 219:774–777.PubMed Aoki J, Watanabe H, Shinozaki T, et al. FDG PET of primary benign and malignant bone tumors: standardized uptake value in 52 lesions. Radiology 2001; 219:774–777.PubMed
18.
Zurück zum Zitat Arsos G, Venizelos I, Karatzas N, et al. Low grade chondrosarcomas: a difficult target for radionuclide imaging. Eur J Radiol 2002; 43:66–72.CrossRefPubMed Arsos G, Venizelos I, Karatzas N, et al. Low grade chondrosarcomas: a difficult target for radionuclide imaging. Eur J Radiol 2002; 43:66–72.CrossRefPubMed
19.
Zurück zum Zitat Hammacher K, Coenen HH, Stocklin G. Efficient stereospecific synthesis of no-carrier-added 2-[18F]fluoro-2-deoxy-d-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 1986; 27:235–238.PubMed Hammacher K, Coenen HH, Stocklin G. Efficient stereospecific synthesis of no-carrier-added 2-[18F]fluoro-2-deoxy-d-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 1986; 27:235–238.PubMed
20.
Zurück zum Zitat Pritchard D, Unni K. Chondrosarcoma. International Skeletal Society closed meeting syllabus, Stockholm, Sweden, Aug 25, 1992. Pritchard D, Unni K. Chondrosarcoma. International Skeletal Society closed meeting syllabus, Stockholm, Sweden, Aug 25, 1992.
21.
Zurück zum Zitat Personal communication, Prof. G. Steiner, Chief of Pathology, Orthopedic Institute, NYC. Personal communication, Prof. G. Steiner, Chief of Pathology, Orthopedic Institute, NYC.
22.
Zurück zum Zitat Bredella M, Caputo GR, Steinbach LS. Value of PDG positron imaging in conjunction with MRI for evaluating therapy response in patients with musculoskeletal sarcomas. AJR Am J Roentgenol 2002; 179:1145–1150.PubMed Bredella M, Caputo GR, Steinbach LS. Value of PDG positron imaging in conjunction with MRI for evaluating therapy response in patients with musculoskeletal sarcomas. AJR Am J Roentgenol 2002; 179:1145–1150.PubMed
23.
Zurück zum Zitat Franzius C, Sciuk, J, Brinkschmidt C, et al. Evaluation of chemo-therapy response in primary bone tumors with F-18 FDG positron emission tomography compared with histologically assessed tumor necrosis. Clin Nucl Med 2000; 25:874–881.CrossRefPubMed Franzius C, Sciuk, J, Brinkschmidt C, et al. Evaluation of chemo-therapy response in primary bone tumors with F-18 FDG positron emission tomography compared with histologically assessed tumor necrosis. Clin Nucl Med 2000; 25:874–881.CrossRefPubMed
24.
Zurück zum Zitat Franzius C, Daldrup-Link, H, Wagner-Bohn A, et al. FDG-PET for detection of recurrences from malignant primary bone tumors: comparison with conventional imaging. Ann Oncol 2002; 13:157–160.CrossRefPubMed Franzius C, Daldrup-Link, H, Wagner-Bohn A, et al. FDG-PET for detection of recurrences from malignant primary bone tumors: comparison with conventional imaging. Ann Oncol 2002; 13:157–160.CrossRefPubMed
25.
Zurück zum Zitat Zasadny KR, Wahl RL. Standardized uptake values in normal tissues at PET with 2-(F18) fluoro-2-deoxy-d-glucose. Variations with body weight and a method for correction. Radiology 1993; 89:847–850. Zasadny KR, Wahl RL. Standardized uptake values in normal tissues at PET with 2-(F18) fluoro-2-deoxy-d-glucose. Variations with body weight and a method for correction. Radiology 1993; 89:847–850.
26.
Zurück zum Zitat Kubota R, Yamada S, Kubota K, et al. Intratumoral distribution of fluorine 18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissue studied by microautoradiography. J Nucl Med 1992; 33:1972–1980.PubMed Kubota R, Yamada S, Kubota K, et al. Intratumoral distribution of fluorine 18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissue studied by microautoradiography. J Nucl Med 1992; 33:1972–1980.PubMed
27.
Zurück zum Zitat Guhlmann A, Brechy-Krauss D, Suger G, et al. Chronic osteomyelitis: detection with FDG PET and correlation with histopathologic findings. Radiology 1998; 206:749–754.PubMed Guhlmann A, Brechy-Krauss D, Suger G, et al. Chronic osteomyelitis: detection with FDG PET and correlation with histopathologic findings. Radiology 1998; 206:749–754.PubMed
Metadaten
Titel
18FDG-PET applications for cartilage neoplasms
verfasst von
Frieda Feldman
Ronald Van Heertum
Chitra Saxena
May Parisien
Publikationsdatum
01.07.2005
Verlag
Springer-Verlag
Erschienen in
Skeletal Radiology / Ausgabe 7/2005
Print ISSN: 0364-2348
Elektronische ISSN: 1432-2161
DOI
https://doi.org/10.1007/s00256-005-0894-y

Weitere Artikel der Ausgabe 7/2005

Skeletal Radiology 7/2005 Zur Ausgabe

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

S3-Leitlinie zu Pankreaskrebs aktualisiert

23.04.2024 Pankreaskarzinom Nachrichten

Die Empfehlungen zur Therapie des Pankreaskarzinoms wurden um zwei Off-Label-Anwendungen erweitert. Und auch im Bereich der Früherkennung gibt es Aktualisierungen.

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

18.04.2024 Pädiatrische Notfallmedizin Nachrichten

Im Choosing-Wisely-Programm, das für die deutsche Initiative „Klug entscheiden“ Pate gestanden hat, sind erstmals Empfehlungen zum Umgang mit Notfällen von Kindern erschienen. Fünf Dinge gilt es demnach zu vermeiden.

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

13.04.2024 Klinik aktuell Kongressbericht

Die Teilnehmer eines Forums beim DGIM-Kongress waren sich einig: Fehler in der Medizin sind häufig in ungeeigneten Prozessen und mangelnder Kommunikation begründet. Gespräche mit Patienten und im Team können helfen.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.